Trial Profile
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary) ; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Glandular and epithelial neoplasms; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms DICE
- 22 Mar 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 05 Apr 2022 Trial design published in the Trials
- 10 Mar 2022 Status changed from recruiting to active, no longer recruiting.